Axovant Gene Therapies candidate nabs Uncommon Pediatric Illness tag for nerve cell dysfunction (NASDAQ:AXGT)

Author

Categories

Share

The FDA grants Rare Pediatric Disease designation to Axovant Gene Therapies’ (NASDAQ:AXGT) AXO-AAV-GM1, an AAV9-based gene remedy for the GM1 gangliosidosis, a uncommon inherited dysfunction characterised by the progressive destruction of nerve cells (neurons) within the mind and spinal wire.

Uncommon Pediatric Illness designation supplies for the issuance of a precedence evaluation voucher following FDA approval. The voucher can be utilized for accelerated approval of a future software or it may be offered to a 3rd celebration.

A Phase 1/2 clinical trial is in course of.

Quant score is Impartial. 

Author

Share